Walmart Inc. (NYSE:WMT) Goldman Sachs Global Retailing Conference Call September 4, 2024 11:00 AM ET Company Participants Manish Joneja - Senior Vice President, Walmart US Marketplace and WFS Conference Call Participants Kate McShane - Goldman Sachs Kate McShane Okay. Good morning, everyone. Thank you for joining us. It's my pleasure to introduce Walmart and to moderate this fireside chat. We're very excited to have with us Manish Joneja, today, Senior Vice President of Walmart US Marketplace and Walmart Fu ...

Zoetis Inc (NYSE:ZTS) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 1:05 PM ET Company Participants Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Erin Wright Thanks, and good afternoon, everyone. Welcome to the Morgan Stanley Healthcare Conference. I'm Erin Wright, Lead Healthcare Services Analyst at Morgan Stanley. We're happy to have with us today, Zoetis' CEO, Kristin Peck with us; as ...

American Express Company (NYSE:AXP) 25th Annual Scotiabank Financials Summit 2024 Conference September 4, 2024 11:50 AM ET Company Participants Anna Marrs - Group President of Global Commercial Services and Credit & Fraud Risk Unidentified Company Representative So, I'm delighted to start our keynote presentation of the day. It's really a pleasure to call to the stage Anna Marrs, Group President, Global Commercial Services and Credit and Fraud Risk at American Express. And we're so excited. This is the firs ...

Dell Technologies Inc. (NYSE:DELL) Citi 2024 Global TMT Results Conference September 4, 2024 11:40 AM ET Company Participants Michael Dell - Chairman & CEO Conference Call Participants Asiya Merchant - Citi Philip Drury - Citi Philip Drury Well, look, it's a great pleasure to warmly welcome all of you to our Citi Global Tech Media Telecom Conference 2024. My name is Philip Drury, I'm the Global Head of TMT Investment Banking at Citi. This is the first time we're bringing together both corporates and investo ...

The Williams Companies, Inc. (NYSE:WMB) Barclays 38th Annual CEO Energy-Power Conference September 4, 2024 12:40 PM ET Company Participants Alan Armstrong - President and Chief Executive Officer Unidentified Company Representative Good afternoon, everyone. Welcome, and thank you for attending. It is my pleasure to introduce our next company, Williams; and from Williams, we have Alan Armstrong CEO. Welcome. Alan Armstrong Well, thank you, and appreciate everybody being here today. We've got a great story to ...

Boston Scientific Corporation (NYSE:BSX) Wells Fargo 2024 Healthcare Conference September 4, 2024 8:00 AM ET Company Participants Brad Sutton - Chief Medical Officer, AF Solutions Jon Monson - SVP, IR Michael F. Mahoney - Chairman and CEO Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Lawrence Biegelsen Okay. Good morning and welcome to the 2024 Wells Fargo Healthcare Conference. I'm Larry Biegelsen, the medical device analyst. This our first session at the conference. I'm thrilled ...

Prudential Financial, Inc. (NYSE:PRU) KBW Insurance Conference September 4, 2024 10:50 AM ET Company Participants Charlie Lowrey - Chairman and CEO Conference Call Participants Ryan Krueger - Managing Director, KBW Ryan Krueger All right. Good morning, everyone. I'm Ryan Krueger, the Life Insurance Analyst at KBW. Really pleased to be joined today with Charlie -- by Charlie Lowrey, the Chairman and CEO of Prudential. Charlie Lowrey Thank you for having me. Question-and-Answer Session Q - Ryan Krueger So to ...

Dollar General Corporation (NYSE:DG) Goldman Sachs 31st Annual Global Retailing Conference September 4, 2024 12:30 PM ET Company Participants Todd Vasos – Chief Executive Officer Kelly Dilts – Executive Vice President and Chief Financial Officer Kevin Walker – Vice President of Investor Relations Conference Call Participants Kate McShane – Goldman Sachs Kate McShane Get started. We are now officially in the afternoon session of Day 1 of the Goldman Sachs 31st Annual Global Retailing Conference. It is my ple ...

Pfizer Inc. (NYSE:PFE) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 8:30 AM ET Company Participants David Denton - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right, great. We're going to get started here. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. Very pleased to be hosting Pfizer this morning, CFO, Dave Denton. I'm Terence Flynn from ...

Company and Industry Overview * **Company**: Johnson & Johnson (NYSE: JNJ) * **Industry**: Healthcare, Pharmaceuticals, Medical Technology Key Points Growth Targets and Confidence * **2025 Revenue Growth**: Johnson & Johnson aims for more than 3% revenue growth in 2025, with a focus on Innovative Medicine Group (IMG) growing 5% to 7% from 2025 to 2030. * **Confidence Source**: The company's strong performance in 2024, with total revenue growth of over 7% and EPS growth of 11%. * **Growth Drivers**: * **Innovative Medicine**: Multiple myeloma, prostate cancer, neuroscience, and pulmonary arterial hypertension franchises. * **MedTech**: Vision franchise (ACUVUE OASYS MAX), cardiovascular (PFA catheters, Impella, Shockwave), and orthopedic (VELYS robotics, OTTAVA robotic system). * **Regulatory Milestones and Data Readouts**: Nipocalimab in myasthenia gravis, TARIS in non-muscle invasive bladder cancer, oral IL-23 in psoriasis and IBD, and RYBREVANT plus LAZCLUZE in EGFR mutated NSCLC. Mergers and Acquisitions (M&A) * **Focus**: Growth MedTech assets and early-stage deals in innovative medicine. * **Investment**: Approximately $18 billion in M&A in the first half of 2024, including acquisitions of Shockwave, V-Wave, Ambrx, Proteologics, and yellow jacketing bispecific antibodies. * **Criteria**: Strategic, scientific, and financial considerations. IRA Medicare Part D Negotiations * **Impact**: Negative impact on innovation and R&D investment. * **Adaptation**: * Multiple parallel indication seeking. * Development of subcutaneous formulations for biologics. * Focus on first-in-class and best-in-class medicines. Pipeline Assets * **Oral IL-23 Inhibitor**: Phase II data in psoriasis showed impressive efficacy, with PASI 75 data around 70% and PASI 100 data around 40%. * **TREMFYA**: Phase II data in IBD showed high levels of endoscopy complete remission, with approximately 1/3 of patients showing no evidence of disease after one year. * **TAR-200**: Med device combo for bladder cancer, with unprecedented rates of complete response and breakthrough designation from the FDA. * **RYBREVANT-lazertinib**: Combination therapy for EGFR mutated NSCLC, with promising data in progression-free survival and overall survival. Other Important Points * **Obesity**: Interest in exploring differentiated assets in obesity, particularly those targeting hunger and satiation in the brain. * **Talc Litigation**: Prepackaged bankruptcy for ovarian cancer claims, with confidence in achieving the required 75% voting threshold. * **Market Positioning**: The oral IL-23 inhibitor is positioned as a treatment option for patients who do not want to use injectables or are not candidates for advanced therapies.